Faegre Drinker represented Allievex Corporation, a biopharmaceutical company based in Boston, Massachusetts, in connection with the in-licensing from BioMarin Pharmaceutical Inc. of exclusive worldwide rights to develop and commercialize an enzyme replacement therapy to treat mucopolysaccharidosis type IIIB (MPS IIIB), a rare pediatric neurodegenerative disease.
October 2019
Allievex Corporation Enters Licensing Agreement With BioMarin Pharmaceutical
United States - Massachusetts
